按大小分类的氨基酸 — 解决异亮氨酸到亮氨酸替代的问题

快速解答

Sorting amino acids by size sounds straightforward until a project uses the ranking to choose a substitution. Does “size” mean molecular mass, side-chain volum…

按大小分类的氨基酸 — 解决异亮氨酸到亮氨酸替代的问题

Sorting amino acids by size sounds straightforward until a project uses the ranking to choose a substitution. Does “size” mean molecular mass, side-chain volume, a steric feature in a particular structure, or behavior in a solvent? These are different quantities. A list ordered by mass cannot automatically answer a question about how a residue fits in a binding site.

Consider an explicitly hypothetical failure: a student replaces isoleucine with leucine in a research peptide because a spreadsheet presents them as interchangeable entries in a size category. The variant then fails the project’s assay criterion. This is an invented teaching scenario with no measured values. The observation is an altered assay outcome; the explanation remains unresolved.

The baseline is H-GIAS-OH and the variant H-GLAS-OH, both linear four-residue peptides with free ends, 手性残基处的 L 构型, 并且没有有意的修改. The change is at position 2. The task is to determine whether the original size assumption was justified and what evidence could explain the hypothetical result.

Define the size metric before interpreting the ranking

I and L identify Ile and Leu under the standard residue convention. Their equal composition gives equal tabulated mass, but their side chains connect differently. A mass ranking therefore cannot establish equivalent packing or functional behavior at position 2 of the hypothetical target.

A molecular-mass table answers a composition-based question. A side-chain-volume scale uses a particular definition and reference framework. A structural assessment asks about spatial relationships in a specific molecular context. Before using any of these, record the definition and source rather than keeping only a column labeled “size.”

按大小分类的氨基酸 — 解决异亮氨酸到亮氨酸替代的问题

Write the connectivity explicitly. Leucine’s side chain can be represented as –CH2–CH(CH3)2, whereas isoleucine’s is –CH(CH3)–CH2–CH3, with each expression attached to the alpha carbon at the left. Both contain four side-chain carbons, but isoleucine branches at the first side-chain carbon and leucine at the next. A local contact near the backbone can therefore pose a different geometric question even when total atom counts and mass coincide.

This comparison does not predict which fits a specific binding site. A site might favor one arrangement, tolerate both or be affected by other changes in the peptide. A structural hypothesis should name the relevant contact or constraint, rather than using “same size” as an explanation after the assay result is known.

残留物 单同位素残留质量, 和 Average residue contribution, 克/摩尔 What this ranking means
G, 甘氨酸 57.02146 57.0519 Lower mass in this selected comparison
一个, 翼 71.03711 71.0788 A mass value, not a measured spatial volume
V, 瓦尔 99.06841 99.1326 Higher mass than Ala under this convention
我, 和 113.08406 113.1594 Equal mass to Leu
L, 亮氨酸 113.08406 113.1594 Equal mass does not establish identical side-chain shape
F, 苯丙氨酸 147.06841 147.1766 An aromatic residue with a different chemical structure
瓦, 色氨酸 186.07931 186.2132 Higher mass in this selected set, not a universal steric ranking

这 ExPASy 质量表 supplies these rounded residue values. The table ranks mass for the selected set; it does not report measured side-chain volumes or a universal steric order. Keep a volume or structural-fit question separate from this composition calculation.

If a project needs a volume comparison, choose a defined and relevant volume source. Do not invent values or translate mass into volume without a justified model. If a specific binding-site fit is the concern, a generic volume ranking may still leave the decisive structural question unanswered.

Configuration adds another distinction. Isoleucine has a side-chain stereocenter in addition to its alpha-carbon center; leucine does not have the analogous configured branching center. 这 IUPAC stereochemical recommendations distinguish alpha-carbon L/D descriptors from other centers and discuss allo terminology. Specify the intended isoleucine form rather than letting a vague “L amino acid” entry carry every stereochemical detail.

按大小分类的氨基酸 — 解决异亮氨酸到亮氨酸替代的问题

烦恼肽 Do not pool the two materials under one expected-mass identifier. The baseline and variant need separate target and sample records even though their mass columns match. If an instrument search reports an unresolved Ile/Leu alternative, retain that limitation instead of selecting the ordered identity by default. Order provenance can support traceability, but it is different from a measurement that distinguishes the alternative side-chain structures.

Separate the observation from competing explanations

In the hypothetical failure, the first observation is that the variant does not meet the chosen assay criterion. That does not prove that its side chain is too large, too small, or incorrectly oriented. It also does not establish that the substitution is the only difference between the tested preparations.

Symptom or record discrepancy 可能的原因 验证证据 下一步
The variant gives a different assay result A relevant structural effect of the substitution A controlled comparison with suitable identity, 数量, and assay evidence Investigate the molecular hypothesis without naming a mechanism prematurely
Equal masses were described as equal size The spreadsheet’s metric was misinterpreted The table definition and original source Relabel the column and reassess the substitution rationale
Different preparations were compared 专注, 溶剂, 容器, or handling differences Preparation records and a matched comparison Resolve these differences before attributing the result to residue identity
Both samples match the expected intact mass The evidence cannot distinguish the intended Ile/Leu alternative Methods appropriate to the actual structural question and sample provenance Do not treat the mass match alone as complete identity confirmation
The sequence or terminal description differs across files A documentation or input error Approved source, accepted order, and analytical sample record Reconcile the target description before interpreting the assay

Peptide Calculator Online The table is a proposed troubleshooting framework. Its causes are hypotheses, 不诊断. A real investigation may identify several contributing factors or conclude that the available evidence cannot distinguish them.

Start by reconstructing what was actually compared. Confirm that the baseline and variant differ only in the intended residue at position 2. Terminal chemistry, 立体化学, 修改, and relevant formulation details should be stated. Unknown symbols or shorthand need clarification rather than a convenient substitution.

Keep three alternatives separate in the investigation: intended Ile-to-Leu constitutional change, a configuration difference within an Ile-containing target, and a preparation or amount difference between otherwise correct materials. All can undermine the original comparison, but the evidence that addresses one may leave another unresolved. A repeat intact-mass measurement can remain compatible with several of them.

按大小分类的氨基酸 — 解决异亮氨酸到亮氨酸替代的问题

Use a counterfactual question to choose the next check. If the size-column label is corrected but the tested samples stay unchanged, only the rationale has changed. If a concentration error is corrected and the assay difference disappears, 肽生物素化 the result supports a preparation explanation rather than a demonstrated steric mechanism. If a properly matched comparison retains a difference, report that bounded observation and investigate the structural explanation separately.

Use mass accounting as a check with a clear limit

The hypothetical GIAS and GLAS sequences contain different residue identities but share elemental composition. With the same free ends and no modifications, their calculated neutral monoisotopic masses are both 346.18522 和. Their calculated average molar masses are both 346.38354 克/摩尔, 大约 346.38 克/摩尔.

For the monoisotopic calculation, the residue contributions are 57.02146 + 113.08406 + 71.03711 + 87.03203 和, followed by one water contribution of 18.01056 和. For the average calculation, the corresponding sum is 57.0519 + 113.1594 + 71.0788 + 87.0782 + 18.01524 克/摩尔. These use the rounded ExPASy entries consistently.

这 RESID residue-accounting explanation supports the single water addition for these free-ended linear Polypeptide Calculator chains. The arithmetic is consistent for both GIAS and GLAS. That agreement is expected from their composition, so it cannot identify which side-chain connectivity is present.

The matching theoretical results illustrate a limitation rather than a proof of interchangeability. An intact mass consistent with one target can also be consistent with the other. The needed identity evidence depends on the actual ambiguity and the method’s capabilities. Do not assume that a routine mass result resolves every side-chain or stereochemical distinction.

Retention differences, when observed, can help distinguish samples under a method but do not by themselves identify which structure is correct. Compare appropriate reference evidence and method capability for the intended distinction. Calling the earlier peak “smaller” or the later peak “more bulky” would attach a structural mechanism that the chromatogram alone does not establish. Peptides From China 螯合肽

These values also exclude counterions, 残留水, and other components of a supplied powder. Equal gross vial masses do not automatically establish equal target amounts entering an assay. Keep the preparation quantity basis separate from theoretical molecular mass.

Correct the decision process, then repeat the relevant comparison

The first correction is documentary: rename the spreadsheet field to the quantity it actually contains, such as “monoisotopic residue mass, Da.” Preserve the original source and units. Remove unsupported claims that equal values establish equal steric behavior.

The second correction is experimental planning. State the hypothesis in a testable form: the Ile-to-Leu change may affect the assay under defined conditions. Identify controls needed to distinguish that possibility from differences in identity, 数量, 配方, or measurement. Do not prelabel the expected outcome as a successful size reduction.

The third correction is interpretive. If a matched comparison supports a reproducible difference, the team can report that difference under its tested conditions. A detailed mechanism may still remain unproven. If the difference disappears after correcting preparation or documentation, that supports a different explanation and should be recorded without forcing the original size hypothesis.

A useful investigation record includes the approved sequences, the size metric originally used, the observed failure, the competing explanations, the evidence reviewed, and the revised conclusion. This makes the lesson transferable to the next substitution without turning one hypothetical case into a universal design rule.

Replace the original “size” claim with the quantity actually used, then state the remaining hypothesis: the position-2 substitution may affect the defined assay. Keep the target identity, amount basis and relevant structural evidence with the result. This turns an ambiguous ranking into a question that can be tested and revised.

常见问题

Can amino acids be ranked by size? 是的, but the metric must be specified. 大量的, a defined volume measure, and steric behavior in a particular structure answer different questions and should not be treated as interchangeable.

Are leucine and isoleucine identical because their masses match? 不. They share elemental composition and tabulated masses but differ in side-chain structure. Equal mass does not establish identical molecular behavior.

Does an assay change prove a steric effect? 不. Structural effects are one possible explanation. 检查身份, 准备, 数量, and method comparability before assigning a cause.

What should replace a vague “size” column? Use the exact descriptor, 单位, definition, and source. State the limits of the inference so that a later reader does not turn a numerical ranking into an unsupported biological prediction.

Xiaoxia Chen

Xiaoxia Chen

新药研发&D 技术员 核心专长: 目标发现, 构效关系 (SAR) 分析, 肽-药物缀合物 (PDC), 以及抗衰老和代谢肽的开发.

轮廓: 陈晓霞领导了多种代谢和肿瘤靶向肽药物的早期发现和临床前研究. 她不仅精通肽库的高通量筛选,还擅长利用人工智能辅助计算生物学进行肽序列从头设计. 现在, 她领导的团队致力于下一代多功能激动剂的深入研究和开发 (比如双- 或三靶点减脂肽) 和高活性组织修复肽.

事实已核实 & 编辑指南
审阅者: 主题专家
分享这篇文章
家 搜索 Whatsapp 服务 产品